Journal article
Development and evaluation of a new triplex immunoassay that detects group a streptococcus antibodies for the diagnosis of rheumatic fever
AL Whitcombe, P Hanson-Manful, S Jack, A Upton, PA Carr, DA Williamson, MG Baker, T Proft, NJ Moreland
Journal of Clinical Microbiology | AMER SOC MICROBIOLOGY | Published : 2020
DOI: 10.1128/JCM.00300-20
Abstract
Streptococcal serology is a cornerstone in the diagnosis of acute rheumatic fever (ARF), a postinfectious sequela associated with group A Streptococcus infection. Current tests that measure anti-streptolysin O (ASO) and anti-DNaseB (ADB) titers require parallel processing, with their predictive value limited by the low rate of decay in antibody response. Accordingly, our objective was to develop and assess the diagnostic potential of a triplex bead-based assay, which simultaneously quantifies ASO and ADB together with titers for a third antigen, SpnA. Our previous cytometric bead assay was transferred to the clinically appropriate Luminex platform by coupling streptolysin O, DNaseB, and SpnA..
View full abstractGrants
Awarded by Heart Foundation
Funding Acknowledgements
This work was funded by the Maurice Wilkins Centre for Biodiscovery and Return on Science. A.L.W. is supported by a University of Auckland Doctoral Scholarship. The RF RISK study, from which some samples were obtained, was funded by the Health Research Council of New Zealand (HRC) Rheumatic Fever Research Partnership (Ministry of Health, Te Puni Kokiri, Cure Kids, Heart Foundation, and HRC). D.A.W. is funded by an Investigator Grant from the National Health and Medical Research Council (GNT1174555).